Abstract: Zwitterionic double network hydrogels, methods for making zwitterionic double network hydrogels, methods for using zwitterionic double network hydrogels, and articles made from and coated with zwitterionic double network hydrogels.

Abstract: A method for delivery of a nucleic acid. comprising administering a lipid nanoparticle composition loaded with the nucleic acid to a subject in which monocytes and/or macrophages have been depleted. thereby delivering the nucleic acid into the subject, the method may more particularly be practiced according to the following steps: a) depleting monocytes and/or macrophages in a subject: and b) administering a lipid nanoparticle composition loaded with the nucleic acid to the subject, thereby delivering the nucleic acid into the subject.

Abstract: Zwitterionic phosphatidylserine (ZPS) monomers, ZPS polymers and ZPS copolymers, methods for making the ZPS monomers, ZPS polymers, and ZPS copolymers, compositions and materials that include ZPS polymers and ZPS copolymers, and methods for using the ZPS monomers, ZPS polymers, and ZPS copolymers.

Abstract: A lipid nanoparticle composition comprising: (i) at least one zwitterionic polymer-containing lipid in which a lipid moiety is covalently attached to a zwitterionic polymer; (ii) at least one non-cationic lipid selected from charged and uncharged lipids, but not attached to a polymer; (iii) at least one cationic or ionizable lipid; and (iv) at least one therapeutic substance, and optionally (v) cholesterol or derivative thereof. Also described herein are methods of delivering a therapeutic substance to a subject, the method comprising administering to the subject a lipid nanoparticle composition described above.

Abstract: Zwitterionic carboxybetaine copolymers and their use in coatings to impart non-fouling and functionality to surfaces, particularly surfaces of blood-contacting medical devices.

Abstract: Compositions of engineered extracellular vesicles for delivery of cargo to targeted tissues and cells are described herein. Also described herein are methods for making and using the extracellular vesicles described herein. Lastly, described herein are methods for treating a subject, the method comprising administering to a subject an extracellular vesicle as described herein.

Abstract: Compositions and methods for modified viral vectors which mitigate the immunogenicity of viral vectors, enabling multiple administrations of viral-based gene delivery viral vectors are described herein. The viral vectors advantageously possess low immunogenicity and comprise at least one immunosuppressive moiety. Also described herein are methods for introducing genetic material into a cell. Additionally, described herein are methods for preparing a modified viral vector. Lastly, described herein are methods for treating a subject, the method comprising administering to a subject a modified viral vector composition as described above.

Abstract: N-oxide and monomers, N-oxide polymers and copolymers, methods for making the N-oxide monomers, polymers, and copolymers, compositions and materials that include N-oxide polymers and copolymers, and methods for using the N-oxide monomers, N-oxide polymers, and N-oxide copolymers.

Abstract: N-oxide and monomers, N-oxide polymers and copolymers, methods for making the N-oxide monomers, polymers, and copolymers, compositions and materials that include N-oxide polymers and copolymers, and methods for using the N-oxide monomers, N-oxide polymers, and N-oxide copolymers.

Abstract: Provided are compositions and methods for the production of modified endonucleases such as CRISPR/Cas9 system with reduced off-target activity. Methods of editing of polynucleotides using the modified endonucleases in vitro and in vivo are also disclosed. In one aspect, the disclosure provides a modified endonuclease, comprising an endonuclease and one or more mixed charge moieties covalently linked to the endonuclease, wherein each mixed charge moiety comprises about 10 to about 400 positively charged moieties and about 10 to about 400 negatively charged moieties, and wherein the ratio of the number of positively charged moieties to the number of negatively charged moieties is from about 1 :0.5 to about 1 :2.

Abstract: Free-standing non-fouling polymers and polymeric compositions, monomers and macromonomers for making the polymers and polymeric compositions, objects made from the polymers and polymeric compositions, and methods for making and using the polymers and polymeric compositions

Abstract: Zwitterionic carboxybetaine copolymers and their use in coatings to impart non-fouling and functionality to surfaces, particularly surfaces of blood-contacting medical devices.

Abstract: Free-standing non-fouling polymers and polymeric compositions, monomers and macromonomers for making the polymers and polymeric compositions, objects made from the polymers and polymeric compositions, and methods for making and using the polymers and polymeric compositions.

Abstract: Zwitterionic carboxybetaine copolymers and their use in coatings to impart non-fouling and functionality to surfaces, particularly surfaces of blood-contacting medical devices.

Abstract: Zwitterionic carboxybetaine copolymers and their use in coatings to impart non-fouling and functionality to surfaces, particularly surfaces of blood-contacting medical devices.

Abstract: High-polymer-density bioconjugate compositions including multi-layer polymer bioconjugates, polymer backfilled bioconjugates, and multi-layer polymer backfilled bioconjugates, and methods for making the compositions.

Abstract: Charged polypeptides, their conjugates, and fusion proteins comprising such polypeptides are disclosed. Inclusion of such a polypeptide in a fusion protein increases the protein's properties such as stability and circulation half-life, which results in a better therapeutic efficacy compared to an active protein alone. Thus, a fusion protein or a conjugate of the disclosure can be useful in developing a protein or peptide drug, treating or preventing diseases, disorders, or conditions, or improving a subjects health or wellbeing.

Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.

Abstract: Zwitterionic double network hydrogels, methods for making zwitterionic double network hydrogels, methods for using zwitterionic double network hydrogels, and articles made from and coated with zwitterionic double network hydrogels.

Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.